Healthcare - Biotechnology - NYSE - US
$ 6.84
-1.87 %
$ 94.4 M
Market Cap
-1.72
P/E
CASH FLOW STATEMENT
-40 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
17.3 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Annovis Bio, Inc.
| Net Income | -56.2 M |
| Depreciation & Amortization | 1 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 4.63 M |
| Change in Working Capital | 2.44 M |
| Others | 11.6 M |
| Free Cash Flow | -40 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (56.2) | (25.3) | (14.5) | (5.5) | (1.0) | (0.7) | (0.7) |
| Depreciation & Amortization | 0 | 0 | 0 | 0.1 | 1.2 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | (0.1) | (1.2) | 0 | 0 |
| Stock Based Compensation | 4.6 | 9.2 | 4.7 | 1.9 | 8.48 K | 82.7 K | 48.5 K |
| Other Operating Activities | 9.2 | 5.9 | 4.4 | 27 K | 84.4 K | 85.4 K | 11.6 K |
| Change in Working Capital | 2.4 | (1.1) | 0.7 | (0.4) | 0.4 | 72.5 K | 96.4 K |
| Cash From Operations | (40.0) | (17.3) | (9.1) | (4.0) | (0.5) | (0.6) | (0.5) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0.5 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.5 | 4.61 K | 95.1 K | 9.22 K | 86.9 K | 0.5 | 0.7 |
| Cash From Financing Activities | 17.3 | 4.61 K | 46.7 | 12.0 | 0.4 | 0.2 | 0.3 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (22.6) | (17.3) | 37.6 | 8.1 | 33.5 K | (0.3) | (0.2) |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (40.0) | (17.3) | (9.1) | (4.0) | (0.5) | (0.6) | (0.5) |